A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

ONC201 is an oral, small molecule selective antagonist of the G protein-coupled receptor DRD2 that causes p53-independent apoptosis in tumor cells via integrated stress response activation and Akt/ERK inactivation. We performed a Phase II study that enrolled 17 patients with recurrent, bevacizumab-n...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrillaga-Romany, Isabel, Chi, Andrew S., Allen, Joshua E., Oster, Wolfgang, Wen, Patrick Y., Batchelor, Tracy T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668041/
https://www.ncbi.nlm.nih.gov/pubmed/29108308
http://dx.doi.org/10.18632/oncotarget.17837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668041/
https://www.ncbi.nlm.nih.gov/pubmed/29108308
http://dx.doi.org/10.18632/oncotarget.17837

Ejemplares similares